Alexis previously served as a Deputy Attorney General for the New Jersey Division of Law, counseling the professional healthcare boards, leading investigative inquiries of licensees pertaining to allegations of professional misconduct before the boards’ Preliminary Evaluation Committee, and counseling the Committee on reinstatements. As a deputy attorney general for NJ CARES, Alexis participated in the Division of Consumer Affairs’ New Jersey Prescription Monitoring Program (NJPMP) Committee, responsible for developing and implementing system enhancements, monitoring and enforcing program compliance, and identifying and referring potential cases of medication abuse, misuse, and diversion amongst patients, prescribers, and pharmacies. Alexis has experience pursuing regulatory initiatives related to combating the opioid epidemic, including the control and monitoring of opioid prescribing for acute and chronic pain, as well as drafting regulatory waivers and administrative orders necessitated by the COVID-19 pandemic. Additionally, Alexis has spearheaded multiple statewide prescriber education initiatives relating to CDS prescribing and drug diversion issues, aimed at training providers on compliance with opioid-related laws and regulations, and the appropriate standard of care for prescribing controlled dangerous substances. Alexis also served on the State Epidemiological Outcomes Workgroup, a statewide committee funded by the Substance Abuse and Mental Health Services Administration to assess addiction prevention initiatives, and served on its Advisory Board. The Workgroup is tasked with the production of a statewide epidemiological profile of substance use, to help guide relevant and effective prevention strategies and gain a more enhanced understanding of the patterns and prevalence of substance abuse in our state.

Through her unique experiences identified above, Alexis has gained a deep understanding and knowledge of opioid-related laws and regulations, the government’s view of what constitutes a violation of these laws and regulations and approach to investigating such violations, and the appropriate discipline for such violations.

At Mandelbaum Barrett PC, Alexis assists healthcare providers and the entities that employ them in (i) complying with opioid-related laws and regulations and avoiding audits, investigations and adverse legal actions, (ii) strategically addressing allegations of overprescribing/indiscriminate prescribing, diversion and departing from the standard of care, including in the context of the off-label prescribing of opioids. Together with her colleagues in the Healthcare and White-Collar Crime Practice Group, Alexis serves an important role in defending healthcare providers against these types of allegations, and (iii) securing reinstatement of their licensure after the suspension/revocation of the same. Having counseled the Committee on reinstatements in their evaluation of reinstatement applications, Alexis is aware of the elements and approach necessary to demonstrate to the Committee that a reinstatement is consistent with the interest of the public.

  • District V A Ethics Committee
  • Jewish Vocational Services of Northeastern New Jersey, Board of Trustees
  • New Jersey Women Lawyers Association

New Jersey

New York

  • Benjamin N. Cardozo School of Law, J.D., 1997
  • University of Chicago, B.A. History, 1994

Healthcare News Alerts

June 6, 2023

COVID-19 OTC TEST KITS The Healthcare Department at Mandelbaum Barrett PC successfully represented a physician practice group that participated in the Biden Harris Over the Counter Test Kit Demonstration (the “Program”) in terminating the suspension of their payments by the Centers for Medicare & Medicaid Services (“CMS”) on the basis of credible allegations of fraud.  […]

Healthcare Alert: CMS Aggressively Targets OTC COVID-19 Test Kit Providers

March 3, 2023

In April of 2022, the Biden-Harris Administration announced that Americans with Medicare Part B, including those enrolled in a Medicare Advantage plan (“Medicare Beneficiaries”), were eligible for up to eight Food and Drug Administration approved, authorized, or cleared over-the-counter COVID-19 test kits per month at no cost under this new program (the “Program”), distributable to […]